成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 28957-04-2 Chemical Structure| 28957-04-2

Structure of Oridonin
CAS No.: 28957-04-2

Chemical Structure| 28957-04-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 28957-04-2

,{[proInfo.pro_purity]}

Oridonin is an antitumor agent, a diterpenoid purified from Rabdosia rubescens. Oridonin interacts with the cysteine 279 of NLRP3 NACHT domain through a covalent bond, abolishes NLRP3-NEK7 interaction, and inhibits consequent activation of NLRP3 inflammasome.

Synonyms: NSC-250682; Isodonol; Oridonine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Krueger, Nadine ; Kronenberger, Thales ; Xie, Hang ; Rocha, Cheila ; Poehlmann, Stefan ; Su, Haixia , et al.

Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chem. phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease's catalytic Cys145 site. Selected potent mols. also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.

Keywords: COVID-19 ; antivirals ; coronavirus ; covalent drugs ; dynamic light scattering ; inhibitors ; main protease ; natural products

Alternative Products

Product Details of Oridonin

CAS No. :28957-04-2
Formula : C20H28O6
M.W : 364.43
SMILES Code : O[C@]12[C@]34[C@](CC[C@](C(C4=O)=C)([H])C3O)([H])[C@@]5(CO2)C(C(C)(CC[C@H]5O)C)([H])[C@@H]1O
Synonyms :
NSC-250682; Isodonol; Oridonine
MDL No. :MFCD00221762

Safety of Oridonin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Oridonin

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 0.5–2 μM 0.5 hours Ori showed dose-dependent inhibitory effects on caspase-1 cleavage, IL-1β secretion, and cell death in BMDMs, but had no effect on TNF-α production. PMC6026158
Human peripheral blood mononuclear cells (PBMCs) 2 μM 0.5 hours Ori suppressed LPS-induced caspase-1 activation and IL-1β secretion in PBMCs, but had no effect on TNF-α production. PMC6026158
Human Umbilical Vein Endothelial Cells (HUVECs) 2 μg/mL 1 hour To evaluate the effect of ORI on Nrf2 nuclear localization in HUVECs, results showed that ORI mediated enhanced Nrf2 nuclear localization by binding to Keap1. PMC10116055
neonatal rat cardiac myocytes (NRCMs) 5, 20, 50 μM 12 or 24 hours Oridonin significantly inhibited Ang II-induced cardiomyocyte hypertrophy, as evidenced by reduced cell size and decreased transcription levels of hypertrophy markers (ANP, BNP, β-MHC). PMC6534559
LoVo cells 22 μM 24 hours Inhibited cell proliferation, invasion, and migration PMC10278272
RKO cells 22 μM 24 hours Inhibited cell proliferation, invasion, and migration PMC10278272
RAW264.7 cells 0.78–3.125 μM 24 hours Inhibited RANKL-induced DC-STAMP mRNA and protein expression, suppressed NFATc1 activation, thereby inhibiting osteoclastogenesis PMC8115576
RAW264.7 cells 0.78–3.125 μM 30 minutes Inhibited RANKL-induced phosphorylation of PLCγ1 PMC8115576
N2a cells 1, 3, 6 μM Ori exerted protective effects on N2a cells and primary neurons against OGD/R-induced injury. PMC10042824
Primary neurons 6 μM Ori exerted protective effects on primary neurons against OGD/R-induced injury. PMC10042824

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice aortic banding (AB)-induced cardiac hypertrophy model Oral 40 mg/kg once daily for 4 weeks Oridonin significantly alleviated pressure overload-induced cardiac hypertrophy and fibrosis, and preserved heart function. Additionally, Oridonin enhanced myocardial autophagy and exerted protective effects through the regulation of P21-related autophagy pathways. PMC6534559
BALB/c Nude mice Subcutaneous xenograft model Oral 160 mg/kg Once daily for 14 days Inhibited tumor growth with no significant organ toxicity PMC10278272
C57BL/6J mice Peritonitis and gouty arthritis models Intraperitoneal injection 20 mg/kg Single injection Ori significantly alleviated MSU-induced IL-1β production and neutrophil migration, and prevented MSU injection-induced acute joint swelling and IL-1β production. PMC6026158
C57BL/6 mice LPS-induced acute lung injury model Intravenous injection 5 mg/kg 1 hour To evaluate the anti-inflammatory effect of anti-CD31-ORI-NPs in the acute lung injury model, results showed that anti-CD31-ORI-NPs significantly inhibited neutrophil infiltration, restored vascular endothelial permeability, and reduced ROS and IL-6 production. PMC10116055
Mice Transient middle cerebral artery occlusion (tMCAO) model Intraperitoneal injection 5, 10, 20 mg/kg Single injection Ori reduced the infarct volume and improved neurological deficits in tMCAO mice in a dose-dependent manner. PMC10042824
ICR mice LPS-induced inflammatory bone destruction model intragastric administration 2, 10 mg/kg once daily for 8 days Oridonin attenuated LPS-induced inflammatory bone destruction by suppressing DC-STAMP expression PMC8115576

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.72mL

2.74mL

1.37mL

27.44mL

5.49mL

2.74mL

References

 

Historical Records

Categories